Icatibant Sandoz

Icatibant, the active ingredient in Icatibant Sandoz, is a bradykinin B2 receptor antagonist presented as a solution for injection for subcutaneous use. It treats acute attacks of hereditary angioedema type I and type II in patients with this condition.

GNH USA supplies Icatibant Sandoz as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is indicated for the treatment of hereditary angioedema, a condition mediated by excessive bradykinin activity.

- Acute attacks of hereditary angioedema type I: provides rapid reduction of subcutaneous and submucosal swelling by competitively inhibiting the bradykinin B2 receptor. - Acute attacks of hereditary angioedema type II: achieves symptom relief and limits airway obstruction by blocking bradykinin‑mediated vascular permeability.

Icatibant may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the subcutaneous injection site. - Redness or swelling at injection site: localized erythema or edema. - Nausea: transient feeling of queasiness. - Headache: mild headache occurring shortly after administration. - Fever: low‑grade temperature increase. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reactions: including rash, urticaria, or anaphylaxis requiring immediate medical attention. - Severe hypotension: rare drop in blood pressure following injection. - Thrombocytopenia: very rare decrease in platelet count. - Liver enzyme elevation: rare increase in transaminases. - Angioedema of the airway: potentially life‑threatening swelling requiring emergency care.

When using Icatibant, certain precautions should be observed to ensure safe administration.

- Renal impairment: monitor for accumulation as clearance may be reduced. - Hepatic dysfunction: use with caution; limited data on safety. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Breastfeeding: unknown excretion; consider alternatives. - Concomitant ACE inhibitors: may increase bradykinin levels, raising risk of angioedema. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that influence bradykinin pathways or affect its pharmacokinetics.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels, raising risk of angioedema. - Angiotensin receptor blockers (ARBs): similar risk of enhanced bradykinin effects. - DPP‑4 inhibitors: potential additive effect on bradykinin metabolism.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate swelling if angioedema occurs. - C1‑esterase inhibitor concentrates: concurrent use may not provide additional benefit; monitor clinical response.